Products are for professional/laboratory use only.
The Serum CrossLaps® (CTX-I) ELISA assay is an enzyme immunological test for the quantification of degradation products of C-terminal telopeptides of Type I collagen in human serum and plasma.
It is intended for in-vitro diagnostic use as an indication of human bone resorption and may be used as an aid in:
Monitoring bone resorption changes of:
a) Anti-resorptive therapies in postmenopausal women:
- Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
- Bisphosphonate therapies
b) Anti-resorptive therapies in individuals diagnosed with osteopaenia:
- Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
- Bisphosphonate therapies
Predicting skeletal response (Bone Mineral Density) in postmenopausal women undergoing anti-resorptive therapies:
a) Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
b) Bisphosphonate therapies
Unique Features
- Management of Postmenopausal Osteoporosis
- Prediction of long-term skeletal response to anti-resorptive therapies, e.g. HRT, bisphosphonates
- Increase in patient motivation and compliance
- Assessment of Bone Resorption in Patients
- With metabolic bone disease, e.g. hyperparathyroidism, Paget´s disease, osteodystrophy
- Receiving prolonged glucocorticoid therapy
- A reference marker for osteoporosis management as indicated by IOF, IFCC and NBHA
- Easy to perform – one step incubation
- Excellent correlation with automated methods
